Spyre Therapeutics (SYRE) EBT Margin (2015 - 2023)
Spyre Therapeutics' (SYRE) quarterly EBT Margin came in at 31551.45% in Q2 2023, down 2798121.0% YoY from N/an in Q2 2022, and down 238.45% on a QoQ basis from 9322.22% in Q1 2023.
Spyre Therapeutics (SYRE) EBT Margin (2015 - 2023) Analysis & Trends
Spyre Therapeutics (SYRE) has 7 years of EBT Margin data on file, last reported at 31551.45% in Q2 2023.
- Quarterly EBT Margin fell 2798121.0% year-over-year to 31551.45% in Q2 2023, while the trailing twelve-month figure through Mar 2024 was 52933.58% (down 4623838.0% YoY) and the FY2023 annual result came in at 38241.08%, down 3463649.0% from the prior year.
- EBT Margin slipped to 31551.45% in Q2 2023, from 9322.22% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 49.2% in Q2 2021 to a low of 31551.45% in Q2 2023.
- A 3-year average of 7644.12% and a median of 3570.24% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin tumbled 352104 bps — and 2023, when it tumbled 2798121 bps.
- Tracing SYRE's EBT Margin over 3 years: stood at 560.46% in 2021, then sank by 1895 bps to 11180.95% in 2022, then slumped by 182 bps to 31551.45% in 2023.
- The last three EBT Margin figures came in at 31551.45% (Q2 2023), 9322.22% (Q1 2023), and 11180.95% (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -31,551.45% |
| Mar 31, 2023 | -9,322.22% |
| Dec 31, 2022 | -11,180.95% |
| Sep 30, 2022 | -10,599.43% |
| Jun 30, 2022 | -3,570.24% |
| Mar 31, 2022 | -1,794.13% |
| Dec 31, 2021 | -560.46% |
| Sep 30, 2021 | -169.01% |
| Jun 30, 2021 | -49.20% |
| Jun 30, 2018 | -407.57% |
| Mar 31, 2018 | -545.76% |
| Dec 31, 2017 | -441.81% |
| Sep 30, 2017 | -623.47% |
| Jun 30, 2017 | -447.60% |
| Mar 31, 2017 | -664.66% |
| Dec 31, 2016 | -474.02% |
| Sep 30, 2016 | -568.32% |
| Jun 30, 2016 | -394.83% |
| Mar 31, 2016 | -528.64% |
| Dec 31, 2015 | -430.22% |